Back to all assets

DaVita DVA

equity

Price History

$0.958$80.67$160.38$240.09
1995-10 · DCA start$4.07

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-91.7%-61.1%-30.6%-0.0%
1995-102026-08 · -24.4%

Worst drawdown: −92%, peaking Jun 1998 and bottoming Apr 2000 — 64 months below the prior high before recovering.

DCA Backtest

Invested
$37,100
Value today
$479,298
Return
+1191.9%
Months invested
371

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $57,174 today, so the real (inflation-adjusted) return is +738.3%.

Lump sum instead — $37,100 all at once in Oct 1995: $1,652,430 (+4354.0%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jul 2026): $175.6 on $200 invested (-12.2%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1995-10: +1191.9%

About DaVita

DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. (Wikipedia)

It's a listed company categorised under health care and health care services, with a market cap of about $11.6B.

It rates High Risk at 3.1/5, meaning several rated factors score badly, so this carries materially more risk than a typical holding.

What pushes the score up: market / volatility (4.0/5) and earnings quality (4.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

High Risk(3.1/5)80% rated

How these ratings work

Market / Volatility4.0/5 · weight 20%
  • Annualised volatility (3yr)4/545.5
  • Max drawdown from ATH5/591.7
  • Beta vs S&P 5003/50.91
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5185.9m
  • Float % of shares outstandingnot yet researched
Leverage / Financial3.0/5 · weight 20%
  • Debt / equitynot yet researched
  • Interest coverage (EBIT / interest)3/53.8
Earnings Quality4.0/5 · weight 15%
  • 3yr EPS volatility4/537.4
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.